The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab.
 
Philip C. Mack
Honoraria - Guardant Health
Consulting or Advisory Role - Amgen; AstraZeneca; Guardant Health
Research Funding - Boehringer Ingelheim
 
Mary Weber Redman
Consulting or Advisory Role - Ignyta; Ignyta
 
James Moon
No Relationships to Disclose
 
Sarah B. Goldberg
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Lilly; Spectrum Pharmaceuticals
Research Funding - AstraZeneca; Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Pfizer (Inst); Spectrum Pharmaceuticals (Inst)
 
Roy S. Herbst
Leadership - Junshi Pharmaceuticals
Consulting or Advisory Role - Abbvie; ARMO Biosciences; AstraZeneca; Biodesix; Bolt Biotherapeutics; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; Genmab; Halozyme; Heat Biologics; I-Mab; Immunocore; Infinity Pharmaceuticals; Junshi Pharmaceuticals; Lilly; Loxo; Merck; Midas Health Analytics; Mirati Therapeutics; Nektar; Neon Therapeutics; NextCure; Novartis; Pfizer; Sanofi; Seagen; Shire; Spectrum Pharmaceuticals; Symphogen; Takeda; TESARO; Tocagen
Research Funding - AstraZeneca; Genentech/Roche; Lilly; Merck
 
Mary Ann C. Melnick
Research Funding - AstraZeneca (Inst); Genentech (Inst)
 
Zenta Walther
No Relationships to Disclose
 
Fred R. Hirsch
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Genentech; Lilly; Loxo; Merck; Novartis; Oncocyte; Pfizer; Roche
Research Funding - Abbvie (Inst); Amgen (Inst); Biodesix (Inst); Merck (Inst); Mersana (Inst); Rain Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - EGFR FISH and IHC for prediction of outcome in patients treated with EGFR inhibitors (Inst)
 
Katerina A. Politi
Consulting or Advisory Role - AstraZeneca; Dynamo Therapeutics; Maverick Therapeutics
Research Funding - AstraZeneca (Inst); Kolltan Pharmaceuticals (Inst); Roche (Inst); Symphogen (Inst)
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a patent licensed by MSKCC to Molecular MD for T790M testing
Travel, Accommodations, Expenses - AstraZeneca; Maverick Therapeutics
 
Karen Kelly
Honoraria - Merck
Consulting or Advisory Role - Abbvie; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; Inivata; Merck; Novartis; Pfizer; Regeneron; Symphogen
Research Funding - Abbvie (Inst); Astellas Pharma; Bristol-Myers Squibb; EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Regeneron (Inst); Tizona Therapeutics, Inc.; Transgene
Patents, Royalties, Other Intellectual Property - Author Royalties for UpToDate, an evidence based, peer reviewed information resource, available via the web, desktop, and PDA.
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; EMD Serono; Genentech/Roche; Lilly; Merck; Merck; Regeneron
 
David R. Gandara
Consulting or Advisory Role - Amgen; AstraZeneca (Inst); Boehringer Ingelheim; CellMax Life (Inst); Guardant Health (Inst); Inivata; IO Biotech (Inst); Lilly; Merck; OncoCyte (Inst); Pfizer; Roche/Genentech
Research Funding - AstraZeneca/MedImmune (Inst); Merck (Inst); Merck (Inst); Roche/Genentech (Inst)